OPDIVO + YERVOY

OS in tumor cell PD-L1 TC ≥ 1 %

4 months survival benefit and a 38 % reduced risk of death with OPDIVO + YERVOY.

Minimum follow-up: 28.8 months

Response rates in patients with tumor-cell PD-L1 ≥ 1 %

Minimum follow-up: 28.8 months.

Reference:

Kato K, Doki Y, Chau I, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024;13:e7235. doi:10.1002/cam4.7235

7356-NO-2500069 / Developed 11.11.2025